MEDTECHS DEFLATE FURTHER
13/03/25 -"It has been some time since AlphaValue last bashed MedTechs, its recurring bête noire when it comes to lofty valuations. In fairness the sector has taken care of itself of late. Five years after ..."
Pages
64
Language
English
Published on
13/03/25
You may also be interested by these reports :
11/08/26
The Q2 results exceeded the street’s expectations, backed by a healthy uptake of newly launched equipment, intra-ocular lenses and dry eye products, ...
06/08/26
Qiagen’s Q2 results exceeded expectations and management’s guidance. Revenue growth was primarily driven by Sample Technologies and Genomics/NGS. ...
06/08/26
CZM’s Q3 results exceeded expectations, with top-line growth driven by strong performance in Microsurgery. Ophthalmology showed modest growth. The ...
06/08/26
FMC delivered better-than-expected Q2 26 results on revenue and adjusted EBIT, though the margin beat was heavily reimbursement-driven and ...